The pharmacology of curcumin: Is it the degradation products?

Trends in Molecular Medicine

Volumn 18, Issue 3, 2012, Pages 138-144

  Shen, Liang ^a   Ji, Hong Fang ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Alzheimer's disease; Curcumin; Degradation products; Ferulic acid; Pharmacology; Vanillin

Indexed keywords

CURCUMIN;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TISSUE LEVEL; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REDUCTION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CURCUMIN; HUMANS; NEOPLASMS; PROTEOLYSIS;

EID: 84858072552     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.01.004     Document Type: Review

References (75)

1. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 2009, 30:85-94.
2. Goel A., et al. Curcumin as " Curecumin" : from kitchen to clinic. Biochem. Pharmacol. 2008, 75:787-809.
3. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 2010, 62:919-930.
4. Sandur S.K., et al. Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic. Biol. Med. 2007, 43:568-580.
5. Menon V.P., Sudheer A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595:105-125.
6. Aggarwal B.B., et al. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003, 23:363-398.
7. Wilken R., et al. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer 2011, 10:12.
8. Hamaguchi T., et al. Review: curcumin and Alzheimer's disease. CNS Neurosci. Ther. 2010, 16:285-297.
9. Kim J., et al. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem. 2010, 112:1415-1430.
10. Lao C.D., et al. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006, 6:10.
11. Anand P., et al. Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4:807-818.
12. Sharma R.A., et al. Curcumin: the story so far. Eur. J. Cancer 2005, 41:1955-1968.
13. Ireson C.R., et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 2002, 11:105-111.
14. Garcea G., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol. Biomarkers Prev. 2005, 14:120-125.
15. Sharma R.A., et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001, 7:1894-1900.
16. Dhillon N., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.
17. Sharma R.A., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 2004, 10:6847-6854.
18. Cheng A.L., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21:2895-2900.
19. Sandur S.K., et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 28:1765-1773.
20. Ireson C., et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61:1058-1064.
21. Pan M.H., et al. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem. Pharmacol. 2000, 60:1665-1676.
22. Zhou H., et al. The targets of curcumin. Curr. Drug Targets 2011, 12:332-347.
23. Lin J.K. Molecular targets of curcumin. Adv. Exp. Med. Biol. 2007, 595:227-243.
24. Wang Y.J., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 1997, 15:1867-1876.
25. Lin J.K., et al. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000, 13:153-158.
26. Tønnesen H.H., Karlsen J. Studies on curcumin and curcuminoids. VI. Kinetics of curcumin degradation in aqueous solution. Z. Lebensm. Unters. Forsch. 1985, 180:402-404.
27. Holder G.M., et al. The metabolism and excretion of curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] in the rat. Xenobiotica 1978, 8:761-768.
28. Hatcher H., et al. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65:1631-1652.
29. Masuda T., et al. Chemical studies on antioxidant mechanism of curcuminoid: analysis of radical reaction products from curcumin. J. Agric. Food Chem. 1999, 47:71-77.
30. Barnham K.J., et al. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3:205-214.
31. Benson A. Alzheimer's disease: a tangled issue. Drug Discov. Today 2005, 10:749-751.
32. Brown D.R., Kozlowski H. Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases. Dalton Trans. 2004, 1907-1917.
33. Ringman J.M., et al. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2:131-136.
34. Ji H.F., Zhang H.Y. Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol. Sin. 2008, 29:143-151.
35. Lim G.P., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
36. Chandra V., et al. Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 2001, 57:985-989.
37. Vas C.J., et al. Prevalence of dementia in an urban Indian population. Int. Psychogeriatr. 2001, 13:439-450.
38. Porat Y., et al. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem. Biol. Drug Des. 2006, 67:27-37.
39. Baum L., Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 2004, 6:367-377.
40. Yanagisawa D., et al. Curcuminoid binds to amyloid-β1-42 oligomer and fibril. J. Alzheimers Dis. 2011, 24:33-42.
41. Barik A., et al. Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic. Biol. Med. 2005, 39:811-822.
42. Shen L., Ji H.F. Theoretical study on physicochemical properties of curcumin. Spectrochim. Acta A: Mol. Biomol. Spectrosc. 2007, 67:619-623.
43. Thiyagarajan M., Sharma S.S. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci. 2004, 74:969-985.
44. Shen L., et al. Theoretical study on Cu(II)-chelating properties of curcumin and its implications for curcumin as a multipotent agent to combat Alzheimer's disease. J. Mol. Struct. (Theochem) 2005, 757:199-202.
45. Barik A., et al. Comparative study of copper(II)-curcumin complexes as superoxide dismutase mimics and free radical scavengers. Eur. J. Med. Chem. 2007, 42:431-439.
46. Srinivasan M., et al. Ferulic acid: therapeutic potential through its antioxidant property. J. Clin. Biochem. Nutr. 2007, 40:92-100.
47. Makni M., et al. Evaluation of the antioxidant, anti-inflammatory and hepatoprotective properties of vanillin in carbon tetrachloride-treated rats. Eur. J. Pharmacol. 2011, 668:133-139.
48. Kanski J., et al. Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J. Nutr. Biochem. 2002, 13:273-281.
49. Sultana R., et al. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J. Neurochem. 2005, 92:749-758.
50. Makni M., et al. Protective effect of vanillin against carbon tetrachloride (CCl4)-induced oxidative brain injury in rats. Toxicol. Ind. Health 2012, 10.1177/0748233711420472.
51. Ahmed T., Gilani A.H. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol. Biochem. Behav. 2009, 91:554-559.
52. Shahwar D., et al. Acetyl cholinesterase inhibition potential and antioxidant activities of ferulic acid isolated from Impatiens bicolor Linn. J. Med. Plants Res. 2010, 4:260-266.
53. Yan J.J., et al. Protection against betaamyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol. 2001, 133:89-96.
54. Ono K., et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75:742-750.
55. Yang F., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
56. Ono K., et al. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun. 2005, 336:444-449.
57. Tomiyama T., et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 1996, 271:6839-6844.
58. Forloni G., et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001, 487:404-407.
59. Masuda Y., et al. Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β-protein fibrils. Bioorg. Med. Chem. 2011, 19:5967-5974.
60. Patel V.B., et al. Colorectal cancer: chemopreventive role of curcumin and resveratrol. Nutr. Cancer 2010, 62:958-967.
61. Leu T.H., Maa M.C. The molecular mechanisms for the antitumorigenic effect of curcumin. Curr. Med. Chem. Anticancer Agents 2002, 2:357-370.
62. Serafim T.L., et al. Lipophilic caffeic and ferulic acid derivatives presenting cytotoxicity against human breast cancer cells. Chem. Res. Toxicol. 2011, 24:763-774.
63. Lee Y.S. Role of NADPH oxidase-mediated generation of reactive oxygen species in the mechanism of apoptosis induced by phenolic acids in HepG2 human hepatoma cells. Arch. Pharm. Res. 2005, 28:1183-1189.
64. Jung K.J., et al. Suppression of age-related renal changes in NF-kappaB and its target gene expression by dietary ferulate. J. Nutr. Biochem. 2009, 20:378-388.
65. Lirdprapamongkol K., et al. Vanillin enhances TRAIL-induced apoptosis in cancer cells through inhibition of NF-kappaB activation. In Vivo 2010, 24:501-506.
66. Murakami Y., et al. Re-evaluation of cyclooxygenase-2-inhibiting activity of vanillin and guaiacol in macrophages stimulated with lipopolysaccharide. Anticancer Res. 2007, 27:801-807.
67. Ralhan R., et al. Nuclear factor-kappa B links carcinogenic and chemopreventive agents. Front. Biosci. (Schol. Ed.) 2009, 1:45-60.
68. Kampa M., et al. Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. Breast Cancer Res. 2004, 6:R63-R74.
69. Shen L., Ji H.F. Contribution of degradation products to the anticancer activity of curcumin. Clin. Cancer Res. 2009, 15:7108.
70. Dhillon N., et al. Could antitumor activity of curcumin in patients be due to its metabolites? A response. Clin. Cancer Res. 2009, 15:7108-7109.
71. Lin J.K., Shih C.A. Inhibitory effect of curcumin on xanthine dehydrogenase/oxidase induced by phorbol-12-myristate-13-acetate in NIH3T3 cells. Carcinogenesis 1994, 15:1717-1721.
72. Shen L., Ji H.F. Insights into the inhibition of xanthine oxidase by curcumin. Bioorg. Med. Chem. Lett. 2009, 19:5990-5993.
73. Chang Y.C., et al. Structure-activity relationship of C6-C3 phenylpropanoids on xanthine oxidase-inhibiting and free radical-scavenging activities. Free Radic. Biol. Med. 2007, 43:1541-1551.
74. Skrzypczak-Jankun E., et al. Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence. Int. J. Mol. Med. 2000, 6:521-526.
75. Bisht S., Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr. Drug Discov. Technol. 2009, 6:192-199.